Prospective Longitudinal Observational Research in Atopic Dermatitis

NCT04240522 · tracked via the Priya Life Science Switzerland tracker

Sponsor

University of Zurich

Phase

Observational

Started

2017-04-04

Last updated

2026-02-05

Condition(s) studied

Atopic DermatitisAsthmaAtopic Dermatitis and Related Conditions

Study summary

Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march.

Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality.

This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.

Eligibility

Sex

ALL

Min age

1 Year

Max age

85 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Age 0 - 85 years * Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy) * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated The inclusion criteria for healthy controls in this study are as follows: * Age 0 - 85 years * No diagnosis or history of allergic disease * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated Written consent will be obtained after detailed information of the study was given to the participant. Exclusion Criteria \- Unable to give consent or refusal to participate in the study

Primary outcome measure(s)

Remission of atopic dermatitis and associated allergic diseases — 5 years
Prospective observational study

Trial sites (1)

Facility	City	Region	Status
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich	Zurich	Canton of Zurich	Recruiting

More University of Zurich trials in Switzerland

Response Assessment During MR-guided Radiation Therapy for Glioblastoma Recruiting

Assessment of Metabolic Changes in Response to Glcuose Intake in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS) Starting soon

Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy Recruiting

Mastocytosis Registry (of Zurich) Recruiting

MR-informed Stereotactic Radiotherapy for Treatment of Ultracentral Lung Tumours Utilising a Dedicated MR-simulator for Daily Adaptation Followed by CBCT-guided Treatment Delivery Recruiting

Other trials for the same condition

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis Active, not recruiting

Lebrikizumab in Moderate-to-severe Atopic Dermatitis Active, not recruiting

Swiss Paediatric Airway Cohort Recruiting

Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04240522 on ClinicalTrials.gov ↗ ← All trials in Switzerland